TrialSignal transduction and targeted therapy2025

Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial.

Zhan Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.